More on KPRX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-5,300.0% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/6/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Kiora Pharmaceuticals (NQ:KPRX)
Delayed: 2.65 +0.07 (2.71%)
Prev. Close $2.58  
Open$2.59 
52 Wk High$ 
52 Wk Low$ 
Day High$2.65 
Day Low$2.59 
P/E N/A  
EPS$ 
Volume10,485 

Friends, Peers and Foes (?): RBOT WS (more...)

Sep 8, 2026 07:02 AM Kiora Pharmaceuticals names new clinical development chief
Sep 8, 2026 07:02 AM Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
Aug 19, 2026 07:02 AM Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Aug 19, 2026 07:01 AM Form 8-K KIORA PHARMACEUTICALS For: Aug 19
Aug 14, 2026 05:04 PM Form SCHEDULE 13G/A KIORA PHARMACEUTICALS Filed by: ADAR1 Capital Management, LLC
Aug 14, 2026 04:49 PM Form SCHEDULE 13G/A KIORA PHARMACEUTICALS Filed by: Nantahala Capital Management, LLC
Aug 10, 2026 11:59 AM Form SCHEDULE 13G KIORA PHARMACEUTICALS Filed by: PERCEPTIVE ADVISORS LLC
Aug 7, 2026 07:34 AM Kiora Pharmaceuticals (KPRX) Tops Q2 EPS by 17c
Aug 7, 2026 07:03 AM Form 8-K KIORA PHARMACEUTICALS For: Aug 07
Aug 7, 2026 07:03 AM Form 10-Q KIORA PHARMACEUTICALS For: Jun 30
View All Articles

Entities mentioned with KPRX

View All Entities